Steven King - Mar 31, 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role
Director
Signature
/s/ Steven W. King
Stock symbol
OTLC
Transactions as of
Mar 31, 2021
Transactions value $
$0
Form type
4
Date filed
7/16/2021, 05:37 PM
Next filing
Sep 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLC Common Stock Conversion of derivative security +3.29M +8456.14% 3.33M Mar 31, 2021 By Artius Bioconsulting F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLC Series A Convertible Preferred Stock Conversion of derivative security -3.29K -100% 0 Mar 31, 2021 Common Stock 3.29M By Artius Bioconsulting F1, F3
transaction OTLC Stock Options Award $0 +357K $0.00 357K Jul 8, 2021 Common Stock 357K $0.16 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
F2 Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vests immediately on the date of grant.
F3 Shares of the Series A Convertible Preferred Stock does not expire.